#9Health Care· Biotechnology

GILDBuy

Gilead Sciences

$129.58USD

Composite Score67.5Strong

−22

Margin of safety−22%Overvalued

Fair value$105.90

Target$176.13

Loss chance39%

Price (1y)

Loading price history…

Fair price check

4 different valuation methods each estimate what GILD should be worth, then we compare to today's price.

Looks overvalued

Models suggest GILD is trading above fair value

Today's price

$129.58

Median fair price

$105.90

-18% vs today

Of 4 methods:1 say cheap1 say fair2 say pricey

P/E multiplesUndervalued
thinks it's a bargain — estimates $176.13, about 36% above today
EV/EBITDAFair
thinks it's fairly priced — estimates $127.91, about 1% below today
DCF (2-stage)Overvalued
thinks it's expensive — estimates $83.90, about 35% below today
P/B multiplesOvervalued
thinks it's expensive — estimates $53.53, about 59% below today

How to read this: “Cheap” = method's fair price is at least 20% above today. “Fair” = within ±10–20%. “Pricey” = at least 10% below today. Outliers (values more than 5× or less than 0.2× today's price) are excluded.

Fair price ensemble

Median fair

$105.90

Margin of safety

-22.4%

Max (ex-outliers)

$176.13

Tangible BVPS

—

Method	Value
Graham (defensive)	skipped
P/E multiples(vs sector peers)	$176.13
P/B multiples(vs sector peers)	$53.53
EV/EBITDA(vs sector peers)	$127.91
Residual Income	skipped
DCF (2-stage)	$83.90

Median of all applicable methods (current price $129.58). Outliers above 5× or below 0.2× current price are excluded from the max but kept in the median. See methodology for the 6-method ensemble + 7 defenses.

Pillar breakdown

8 dimensions, each scored 0–100 against the universe

Health Care median (n=59)

Quality
Profit margins & asset efficiency
87
Strong
Value
Price vs fundamentals
51
Decent
Growth
Revenue & earnings trajectory
67
Decent
Momentum
Recent price strength
53
Decent
Health
Balance sheet & solvency
68
Decent
Profitability
ROE, ROA, ROIC
83
Strong
Technical
Trend & volatility signals
44
Weak
Risk
Volatility & drawdown profile
73
Strong

0305070100

Strong (70+)Decent (50–70)Weak (30–50)Poor (<30)

Pillars not shown: Sentiment, ML (Phase 5+).

Raw fundamentals (SEC EDGAR)

Metric	Value
Market cap	$160.88B
Revenue (TTM)	$29.74B
Net income (TTM)	$9.22B
Operating cash flow (TTM)	$10.81B
CapEx (TTM)	$576.00M
Free cash flow (TTM)CFO − CapEx	$10.23B
Total assets	$56.28B
Total liabilities	N/A
Stockholders' equity	$23.52B
Cash & equivalents	$5.41B
Shares outstanding	1.24B
EPS (basic)	$1.63
EPS (diluted)	$1.61
P/E ratio (TTM)	17.46

TTM = trailing twelve months. Balance sheet items are point-in-time (latest filing).

Data quality

Latest filed date: 2026-05-07
Latest period end: 2026-04-30
Filing lag: 9 days
Missing metrics: 3(total_liabilities, gross_profit, research_and_development)

Phase 3c — composite is the 8-pillar weighted score over quality, value, growth, momentum, health, profitability, technical, and risk. Sentiment + ML pillars land in Phases 5-6; until then their weight redistributes pro-rata. Fair price is the median of 6 valuation methods (Graham, P/E / P/B / EV-EBITDA multiples, RIM, DCF) with outliers above 5× current price excluded from the max. Risk-overlay flags annotate only — they suppress the entered-top-5 badge but do not modify the composite.